Britta Weigelt
Papers
1
Total Citations
6
H-Index
1
About
Britta Weigelt is a translational cancer researcher whose work bridges molecular pathology and clinical diagnostics, with a primary focus on understanding the genetic and epigenetic drivers of tumor progression. Her most notable contribution centers on the evaluation of TERT mRNA expression as a histopathologic tool, demonstrated in her 2022 study that explored RNAscope® technology for detecting TERT expression in cancer tissues. This work, which has garnered 6 citations, highlights her ability to develop practical diagnostic and prognostic markers that can be directly applied in clinical settings. Weigelt’s research is particularly impactful in the field of cancer genomics, where she investigates how telomerase reactivation influences tumor behavior and patient outcomes. Her studies often combine advanced molecular techniques with rigorous histopathological analysis, offering new insights into tumor heterogeneity and biomarker development. While her citation count reflects the early stage of her career, her work on TERT mRNA expression has already been recognized as a promising avenue for improving cancer diagnosis and risk stratification. Weigelt’s dedication to translating laboratory discoveries into clinically actionable tools positions her as an emerging leader in precision oncology, with her research poised to influence both pathologists and oncologists seeking more accurate ways to classify and treat aggressive cancers.
Research Focus
Key Achievements
Top Papers
- 1